Botox® for idiopathic overactive bladder: efficacy, duration and safety. Effectiveness of subsequent injection

Granese, Roberta; Adile, Giorgio; Gugliotta, Giorgio; Cucinella, Gaspare; Saitta, Salvatore; Adile, Biagio

doi:10.1007/s00404-012-2349-8

Cited by 20 publications

(20 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Granese et al reported on 68 women with ROAB who received 100 U of onabotulinumtoxinA 36. A total of 25 women reported symptom return, 20 of whom underwent a second injection.…”

Section: Repeat Injectionsmentioning

confidence: 99%

OnabotulinumtoxinA for the treatment of overactive bladder

Cox¹,

Cameron²

2014

RRU

View full text Add to dashboard Cite

OnabotulinumtoxinA injection is a safe and effective treatment for adults with refractory overactive bladder. There is sufficient level 1 evidence to support offering onabotulinumtoxinA injections as a second-line treatment to patients who have failed behavioral therapy and oral medications such as antimuscarinics and β3 agonists. An intradetrusor injection of 100 U of onabotulinumtoxinA is likely the optimal dose to balance risks and benefits, and this is the dose approved by the US Food and Drug Administration. Improvement in urgency urinary incontinence episodes, as well as symptom scores and quality of life, were seen in around 60%–65% of patients, and were significantly improved compared with those on placebo. Most studies have reported a duration of symptom relief ranging from 6 to 12 months, with repeat injections being safe and efficacious. Overall, the risk of urinary retention was around 6% across the study populations.

show abstract

“…Granese et al reported on 68 women with ROAB who received 100 U of onabotulinumtoxinA 36. A total of 25 women reported symptom return, 20 of whom underwent a second injection.…”

Section: Repeat Injectionsmentioning

confidence: 99%

OnabotulinumtoxinA for the treatment of overactive bladder

Cox¹,

Cameron²

2014

RRU

View full text Add to dashboard Cite

show abstract

“…[1][2][3][4][5] Meta-analyses of these RCTs report significant improvements in OAB-related outcomes, including incontinence, urodynamics, and patient-reported outcomes (PROs), along with few adverse events. [6][7][8] One such review outlines that 60-65% of patients injected at a 100 U dose reported improvements in urgency incontinence, symptom scores, and quality of life. These patients significantly improved as compared to a placebo group.…”

Section: Introductionmentioning

confidence: 99%

“…Both the de novo and repeateduse subgroups experience significant differences in terms of their pre-/post-injection: frequency, urgency, or incontinence; PROs; and occurrence of adverse events. [6][7][8]11 The limitations of these studies lie in their small sample sizes (often only women) and, while the pre-/post-injection differences may be significant, they do not test if the changes experienced by the subgroups are significantly different. This latter limitation is important to better understand the effect of repeatedly using OnabotA to treat OAB.…”

Section: Introductionmentioning

confidence: 99%

OnabotulinumtoxinA for the treatment of idiopathic overactive bladder is effective and safe for repeated use

Carlson

Civitarese

Baverstock

2017

CUAJ

View full text Add to dashboard Cite

Introduction: The objective of this study was to compare efficacy and safety outcomes between patients receiving onabotulinumtoxinA (OnabotA) for the first time and those receiving a repeat injection. Methods: Data collected before and after OnabotA injection were extracted from a clinical registry. Patients were classified into either first or repeat injection subgroups. Efficacy was measured by the change in use of oral bladder medications, the number of voids per day or night, the frequency of urinary incontinence (UI) episodes, and patient-reported outcomes. Safety was measured by the number of self-reported complications. Differences in safety measures between the subgroups were tested. Results: The analysis included complete data from 81 patients; 30 (37%) receiving OnabotA for the first time, 51 (63%) receiving a repeat injection. Both subgroups reported significant reductions in the use of anticholinergics, more tolerable bladder symptoms, and improvements in patient-reported outcomes. Dry rates were similarly high in both groups (50% and 43%, respectively). There were no statistically significant differences between the subgroups in terms of their safety outcomes. Conclusions: OnabotA is equally as efficacious and safe for patients with overactive bladder receiving a repeat injection as it is for those receiving their first injection.

show abstract

“…The role of WB-MR, especially fused with PET in FDG-PET/MR, in breast cancer imaging is being investigated over the last few years, with promising preliminary results (29); instead, WB-MR has already a well-established role in lymphoma imaging. Its high contrast resolution enables an excellent evaluation of bone marrow, allowing a reliable evaluation marrow lymphomatous involvement (30) and the early identification of osteonecrotic lesions, which are @ C I C E d i z i o n i I n t e r n a z i o n a l i very common in the follow-up of patients who receive chemotherapies and high doses of corticosteroids (31)(32)(33)(34)(35). Furthermore, it provides functional information regarding tissue cellularity through DWI, which is a sequence probing the motion of water molecules in intra-cellular and inter-cellular spaces.…”

Section: @ C I C E D I Z I O N I I N T E R N a Z I O N A L Imentioning

confidence: 99%

A xanthogranulomatous process resembling residual disease on endof- treatment 18f-FDG-PET/CT and Whole Body Magnetic Resonance performed on a primary breast lymphoma treated by ibrutinib plus rituximab-chop

Lagalla

Agrusa²,

Galia

et al. 2016

giog

View full text Add to dashboard Cite

Botox® for idiopathic overactive bladder: efficacy, duration and safety. Effectiveness of subsequent injection

Abstract: We considered the dose of 100 U of Botox(®), for treatment of IDO, as an efficacious and safe solution compared to other therapeutic options, without serious and lasting adverse effects for women, even after a second injection.

Cited by 20 publications

References 30 publications

OnabotulinumtoxinA for the treatment of overactive bladder

OnabotulinumtoxinA for the treatment of overactive bladder

OnabotulinumtoxinA for the treatment of idiopathic overactive bladder is effective and safe for repeated use

A xanthogranulomatous process resembling residual disease on endof- treatment 18f-FDG-PET/CT and Whole Body Magnetic Resonance performed on a primary breast lymphoma treated by ibrutinib plus rituximab-chop

Contact Info

Product

Resources

About